Chemopreventive Effects of Melatonin on Diethylnitrosamine and Phenobarbital-Induced Hepatocarcinogenesis in Male F344 Rats

Nutrition and Cancer

Volumn 47, Issue 2, 2003, Pages 148-155

  Rahman, K M Wahidur ^a,b   Sugie, Shigeyuki ^a   Watanabe, Tomoyuki ^a   Tanaka, Takuji ^c   Mori, Hideki ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLNITROSAMINE; GLUTATHIONE TRANSFERASE; MELATONIN; ORNITHINE DECARBOXYLASE; PHENOBARBITAL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER INCIDENCE; CANCER PREVENTION; CONTROLLED STUDY; DIETARY INTAKE; DRUG STRUCTURE; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; LIVER ADENOMA; LIVER CARCINOGENESIS; LIVER WEIGHT; MALE; NONHUMAN; RAT; STATISTICAL ANALYSIS;

ANIMALIA;

EID: 2342618225     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1207/s15327914nc4702_7     Document Type: Article

References (62)

1. Karbownik M, Reiter RJ, Cabrera J, and Garcia JJ: Comparison of the protective effect of melatonin with antioxidants in the hamster kidney model of estradiol-induced DNA damage. Mutat Res 474, 87-92, 2001.
2. Hardeland R, Reiter RJ, Poeggeler B, and Tan DX: The significance of the metabolism of the neurohormone melatonin: antioxidative protection and formation of bioactive substances. Neurosci Biobehav Rev 17, 347-357, 1993.
3. Reiter RJ, Melchiorri D, Sewerynek E, Poeggeler B, Barlow-Walden L, et al.: A review of the evidence supporting melatonin's role as an antioxidant. J Pineal Res 18, 1-11, 1995.
4. Reiter RJ, Tan DX, Poggeler B, Chen LD, and Menendez-Pelaez A: Melatonin, free radicals and cancer initiation. In Advances in Pineal Research, Maestroni GJM, Conti A, and Reiter RJ (eds). London: Jhon Library, 1997, vol 7.
5. Guerrero JM and Reiter RJ: A brief survey of pineal gland-immune system interrelationships. Endocr Res 18, 91-113, 1992.
6. Reiter RJ: The pineal and its hormones in the control of reproduction in mammals. Endocr Rev 1, 109-131, 1980.
7. Lissoni P: Is there a role for melatonin in supportive care? Support Care Cancer 10, 110-116, 2002.
8. Lans JI, Jaszewski R, Arlow FL, Tureaud J, Luk GD, et al.: Supplemental calcium suppresses colonic mucosal ornithine decarboxylase activity in elderly patients with adenomatous polyps. Cancer Res 51, 3416-3419, 1991.
9. Cos S, Garijo F, Corral J, Mediavilla MD, and Sanchez-Barcelo EJ: Histopathologic features of DMBA-induced mammary tumors in blind-underfed, blind-anosmic, and blind cold-exposed rats: influence of the pineal gland. J Pineal Res 6, 221-231, 1989.
10. Mcikova-Kalicka K, Bojkova B, Adamekova E, Manichova-Chamilova M, Kubatka P, et al.: Preventive effect of indomethacin and melatonin on 7,12-dimethbenz/a/anthracene-induced mammary carcinogenesis in female Sprague-Dawley rats. Folia Biol 47, 75-79, 2001.
11. Anisimov VN, Popovich IG, and Zabezhinski MA: Melatonin and colon carcinogenesis: I. Inhibitory effect of melatonin on development of intestinal tumors induced by 1,2-dimethylhydrazine in rats. Carcinogenesis 18, 1549-1553, 1997.
12. Blask DE (ed): Melatonin in oncology, In Melatonin: Biosynthesis, Physiological Effects and Clinical Applications, Boca Raton, FL: CRC Press, 1993, pp 447-475.
13. Tamarkin L, Cohen M, Roselle D, Reichert C, Lippman M, et al.: Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in the rat. Cancer Res 41, 4432-4436, 1981.
14. Anisimov VN, Kvetnoy IM, Chumakova NK, Kvetnaya TV, Molotkov AO, et al.: Melatonin and colon carcinogenesis. II. Intestinal melatonin-containing cells and serum melatonin level in rats with 1,2-dimethylhydrazine-induced colon tumors. Exp Toxicol Pathol 51, 47-52, 1999.
15. Cos S, Recio J, and Sanchez-Barcelo EJ: Modulation of the length of the cell cycle time of MCF-7 human breast cancer cells by melatonin. Life Sci 54 811-816, 1996.
16. Hill SM and Blask DE: Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res 48, 6121-6126, 1988.
17. Cos S, Blask DE, Lemus-Wilson A, and Hill AB: Effects of melatonin on the cell cycle kinetics and "estrogen-rescue" of MCF-7 human breast cancer cells in culture. J Pineal Res 10, 36-42, 1991.
18. Molis TM, Spriggs LL, Jupiter Y, and Hill SM: Melatonin modulation of estrogen-regulated proteins, growth factors, and proto-oncogenes in human breast cancer. J Pineal Res 18, 93-103, 1995.
19. Menendez-Pelaez A, Poeggeler B, Reiter RJ, Barlow-Walden L, Pablos MI, et al.: Nuclear localization of melatonin in different mammalian tissues: immunocytochemical and radioimmunoassay evidence. J Cell Biochem 53, 373-382, 1993.
20. Imaida K, Hagiwara A, Yoshino H, Tamano S, Sano M, et al.: Inhibitory effects of low doses of melatonin on induction of preneoplastic liver lesions in a medium-term liver bioassay in F344 rats: relation to the influence of electromagnetic near field exposure. Cancer Lett 155, 105-114, 2000.
21. Tan D, Reiter RJ, Chen LD, Poeggeler B, Manchester LC, et al.: Both physiological and pharmacological levels of melatonin reduce DNA adduct formation induced by the carcinogen safrole. Carcinogenesis 15, 215-218, 1994.
22. Karasek M, Reiter RJ, Cardinali DP, and Pawlikowski M: Future of melatonin as a therapeutic agent. Neuroendocrinol Lett 23(suppl 1), 118-121, 2002.
23. Karasek M and Lerchl A: Melatonin and magnetic fields. Neuroendocrinol Lett 23(suppl 1), 84-87, 2002.
24. Erren TC and Stevens RG: [Light, melatonin and internal cancers-recent facts and research perspectives]. Gesundheitswesen 64, 278-283, 2002.
25. Umemura T, Kai S, Hasegawa R, Sai K, Kurokawa Y, et al.: Pentachlorophenol (PCP) produces liver oxidative stress and promotes but does not initiate hepatocarcinogenesis in B6C3F1 mice. Carcinogenesis 20, 1115-1120, 1999.
26. Shiota G, Maeta Y, Mukoyama T, Yanagidani A, Udagawa A, et al.: Effects of Sho-Saiko-to on hepatocarcinogenesis and 8-hydroxy-2′-deoxyguanosine formation. Hepatology 35, 1125-1133, 2002.
27. Blask DE, Sauer LA, Dauchy RT, Holowachuk EW, Ruhoff MS, et al.: Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events. Cancer Res 59, 4693-4701, 1999.
28. Pitot HC and Sirica AE: The stages of initiation and promotion in hepatocarcinogenesis. Biochim Biophys Acta 605, 191-215, 1980.
29. Blask DE: The pineal: an oncostatic gland? In The Pineal Gland, Reiter RJ (ed). New York: Raven Press, 1984, pp 253-284.
30. Aubert C, Janiaud P, and Lecalvez J: Effect of pinealectomy and melatonin on mammary tumor growth in Sprague-Dawley rats under different conditions of lighting. J Neural Transm 47, 121-130, 1980.
31. Philo R and Berkowitz AS: Inhibition of Dunning tumor growth by melatonin. J Urol 139, 1099-1102, 1988.
32. Scherer E and Emmelot P: Kinetics of induction and growth of enzyme-deficient islands involved in hepatocarcinogenesis. Cancer Res 36, 2544-2554, 1976.
33. Williams GM: The significance of chemically-induced hepatocellular altered foci in rat liver and application to carcinogen detection. Toxicol Pathol 17, 663-680, 1989.
34. Naguib M, Hammond DL, Schmid PG III, Baker MT, Cutkomp J, et al.: Pharmacological effects of intravenous melatonin: comparative studies with thiopental and propofol. Br J Anaesth 90, 504-507, 2003.
35. Ubeda A, Trillo MA, House DE, and Blackman CF: A 50 Hz magnetic field blocks melatonin-induced enhancement of junctional transfer in normal C3H/10T1/ 2 cells. Carcinogenesis 16, 2945-2949, 1995.
36. Williams GM: Liver carcinogenesis: the role for some chemicals of an epigenetic mechanism of liver-tumour promotion involving modification of the cell membrane. Food Cosmet Toxicol 19, 577-583, 1981.
37. Imaida K, Taki M, Watanabe S, Kamimura Y, Ito T, et al.: The 1.5 GHz electromagnetic near-field used for cellular phones does not promote rat liver carcinogenesis in a medium-term liver bioassay. Jpn J Cancer Res 89, 995-1002, 1998.
38. Imaida K, Taki M, Yamaguchi T, Ito T, Watanabe S, et al.: Lack of promoting effects of the electromagnetic near-field used for cellular phones (929.2 MHz) on rat liver carcinogenesis in a medium-term liver bioassay. Carcinogenesis 19, 311-314, 1998.
39. Pitot HC, Campbell HA, Maronpot R, Bawa N, Rizvi TA, et al.: Critical parameters in the quantitation of the stages of initiation, promotion, and progression in one model of hepatocarcinogenesis in the rat. Toxicol Pathol 17, 594-611, 1989.
40. Mori H, Ichida T, Tanaka T, and Williams GM: Pathological feature of preneoplastic and neoplastic liver lesions in rodents and humans. In Comparative Ultrastructural Pathology of Selected Tumors in Man and Animals, Schuller HM (ed). pp. 62-96, Boca Raton, FL: CRC Press, 1989, pp 62-96.
41. Ito N, Tsuda H, Tatematsu M, Inoue T, Tagawa Y, et al.: Enhancing effect of various hepatocarcinogens on induction of preneoplastic glutathione S-transferase placental form positive foci in rats-an approach for a new medium-term bioassay system. Carcinogenesis 9, 387-394, 1988.
42. Dragan YP and Pitot HC: The role of the stages of initiation and promotion in phenotypic diversity during hepatocarcinogenesis in the rat. Carcinogenesis 13, 739-750, 1992.
43. Moore MA and Kitagawa T: Hepatocarcinogenesis in the rat: the effect of promoters and carcinogens in vivo and in vitro. Int Rev Cytol 101, 125-173, 1986.
44. Tanaka T, Hirota Y, Kuriyama M, Nishiguchi S, and Otani S: Time course of change in glutathione S-transferase positive foci and omithine decarboxylase activity after cessation of long-term alcohol administration in rats. Asian Pac J Cancer Prev 2, 131-134, 2001.
45. Kitchin KT, Brown JL, and Kulkami AP: Omithine decarboxylase induction and DNA damage as a predictive assay for potential carcinogenicity. Prog Clin Biol Res 369, 137-144, 1991.
46. Pegg AE: Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res 48, 759-774, 1988.
47. Tanaka T, Kojima T, Kawamori T, Yoshimi N, and Mori H: Chemoprevention of diethylnitrosamine-induced hepatocarcinogenesis by a simple phenolic acid protocatechuic acid in rats. Cancer Res 53, 2775-2779, 1993.
48. Olson JW and Russell DH: Prolonged omithine decarboxylase induction in regenerating carcinogen-treated liver. Cancer Res 40, 4373-4380, 1980.
49. Sainz RM, Mayo JC, Rodriguez C, Tan DX, Lopez-Burillo S, et al.: Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Mol Life Sci 60, 1407-1426, 2003.
50. Blask DE, Pelletier DB, Hill SM, Lemus-Wilson A, Grosso DS, et al.: Pineal melatonin inhibition of tumor promotion in the N-nitroso-N-methylurea model of mammary carcinogenesis: potential involvement of antiestrogenic mechanisms in vivo. J Cancer Res Clin Oncol 117, 526-532, 1991.
51. Bojkova B, Kubatka P, Mocikova K, Mnichova M, Ahlersova E, et al.: Effects of retinyl acetate and melatonin on N-methyl-N-nitrosourea-induced mammary carcinogenesis in rats. A preliminary report. Folia Biol 46, 73-76, 2000.
52. Teplitzky SR, Kiefer TL, Cheng Q, Dwivedi PD, Moroz K, et al.: Chemoprevention of NMU-induced rat mammary carcinoma with the combination of melatonin and 9-cis-retinoic acid. Cancer Lett 168, 155-163, 2001.
53. Ahlersova E, Ahlers I, Kubatka P, Bojkova B, Mocikova K, et al.: Melatonin and retinyl acetate as chemopreventives in DMBA-induced mammary carcinogenesis in female Sprague-Dawley rats. Folia Biol 46, 69-72, 2000.
54. Blask DE, Hill SM, Orstead KM, and Massa JS: Inhibitory effects of the pineal hormone melatonin and underfeeding during the promotional phase of 7,12-dimethylbenzanthracene-(DMBA)-induced mammary tumorigenesis. J Neural Transm 67, 125-138, 1986.
55. Seidman MD, Quirk WS, and Shirwany NA: Reactive oxygen metabolites, antioxidants and head and neck cancer. Head Neck 21, 467-479, 1999.
56. Ying SW, Niles LP, and Crocker C: Human malignant melanoma cells express high-affinity receptors for melatonin: antiproliferative effects of melatonin and 6-chloromelatonin. Eur J Pharmacol 246, 89-96, 1993.
57. Pablos MI, Chuang J, Reiter RJ, Ortiz GG, Daniels WM, et al.: Time course of the melatonin-induced increase in glutathione peroxidase activity in chick tissues. Biol Signals 4, 325-330, 1995.
58. Reiter RJ, Tan DX, Poeggeler B, Menendez-Pelaez A, Chen LD, et al.: Melatonin as a free radical scavenger: implications for aging and age-related diseases. Ann NY Acad Sci 719, 1-12, 1994.
59. Batcioglu K, Karagozler AA, Genc M, and Celik S: Comparison of the chemopreventive potentials of melatonin and vitamin E plus selenium on 7,12-dimethylbenz[a]anthracene-induced inhibition of mouse liver antioxidant enzymes. Eur J Cancer Prev 11, 57-61, 2002.
60. Ishizuka M, Yoshino S, Yamamoto Y, Yamamoto H, Imaoka S, et al.: Isozyme selective alterations of the expression of cytochrome P450 during regeneration of male rat liver following partial hepatectomy. Xenobiotica 27, 923-931, 1997.
61. Battalora MS, Kruszewski FH, and DiGiovanni J: Inhibition of chrysarobin skin tumor promotion in SENCAR mice by antioxidants. Carcinogenesis 14, 2507-2512, 1993.
62. Hayes JD and Pulford DJ: The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30, 445-600, 1995.